Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy

Hideyuki Okuma, Ryotaro Bouchi, Seizaburo Masuda, Takato Takeuchi, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 52-year-old woman was treated with sensor augmented pump therapy after undergoing total pancreatectomy for a nonfunctional pancreatic neuroendocrine tumor (NET). The secretion of both endogenous insulin and pancreatic glucagon were completely depleted. Octreotide long acting repeatable (Oct-LAR) was administered for the treatment of liver metastasis of NET. Both the fasting and postprandial glucagon levels decreased immediately after the administration of Oct-LAR. In a continuous glucose monitoring analysis, episodes of nocturnal hypoglycemia was found to increase and an improvement of postprandial hyperglycemia was observed. This case suggests that octreotide may reduce the glucose level in both the fasting and postprandial states, in part by the suppression of extrapancreatic glucagon.

Original languageEnglish
Pages (from-to)3061-3066
Number of pages6
JournalInternal Medicine
Volume56
Issue number22
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Pancreatectomy
Octreotide
Glucagon
Fasting
Neuroendocrine Tumors
Glucose
Hypoglycemia
Hyperglycemia
Insulin
Neoplasm Metastasis
Liver
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy. / Okuma, Hideyuki; Bouchi, Ryotaro; Masuda, Seizaburo; Takeuchi, Takato; Murakami, Masanori; Minami, Isao; Izumiyama, Hajime; Hashimoto, Koshi; Yoshimoto, Takanobu; Ogawa, Yoshihiro.

In: Internal Medicine, Vol. 56, No. 22, 01.01.2017, p. 3061-3066.

Research output: Contribution to journalArticle

Okuma, Hideyuki ; Bouchi, Ryotaro ; Masuda, Seizaburo ; Takeuchi, Takato ; Murakami, Masanori ; Minami, Isao ; Izumiyama, Hajime ; Hashimoto, Koshi ; Yoshimoto, Takanobu ; Ogawa, Yoshihiro. / Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy. In: Internal Medicine. 2017 ; Vol. 56, No. 22. pp. 3061-3066.
@article{f3103e101fb04d7a878bb51cdc21456c,
title = "Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy",
abstract = "A 52-year-old woman was treated with sensor augmented pump therapy after undergoing total pancreatectomy for a nonfunctional pancreatic neuroendocrine tumor (NET). The secretion of both endogenous insulin and pancreatic glucagon were completely depleted. Octreotide long acting repeatable (Oct-LAR) was administered for the treatment of liver metastasis of NET. Both the fasting and postprandial glucagon levels decreased immediately after the administration of Oct-LAR. In a continuous glucose monitoring analysis, episodes of nocturnal hypoglycemia was found to increase and an improvement of postprandial hyperglycemia was observed. This case suggests that octreotide may reduce the glucose level in both the fasting and postprandial states, in part by the suppression of extrapancreatic glucagon.",
author = "Hideyuki Okuma and Ryotaro Bouchi and Seizaburo Masuda and Takato Takeuchi and Masanori Murakami and Isao Minami and Hajime Izumiyama and Koshi Hashimoto and Takanobu Yoshimoto and Yoshihiro Ogawa",
year = "2017",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.8963-17",
language = "English",
volume = "56",
pages = "3061--3066",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "22",

}

TY - JOUR

T1 - Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy

AU - Okuma, Hideyuki

AU - Bouchi, Ryotaro

AU - Masuda, Seizaburo

AU - Takeuchi, Takato

AU - Murakami, Masanori

AU - Minami, Isao

AU - Izumiyama, Hajime

AU - Hashimoto, Koshi

AU - Yoshimoto, Takanobu

AU - Ogawa, Yoshihiro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A 52-year-old woman was treated with sensor augmented pump therapy after undergoing total pancreatectomy for a nonfunctional pancreatic neuroendocrine tumor (NET). The secretion of both endogenous insulin and pancreatic glucagon were completely depleted. Octreotide long acting repeatable (Oct-LAR) was administered for the treatment of liver metastasis of NET. Both the fasting and postprandial glucagon levels decreased immediately after the administration of Oct-LAR. In a continuous glucose monitoring analysis, episodes of nocturnal hypoglycemia was found to increase and an improvement of postprandial hyperglycemia was observed. This case suggests that octreotide may reduce the glucose level in both the fasting and postprandial states, in part by the suppression of extrapancreatic glucagon.

AB - A 52-year-old woman was treated with sensor augmented pump therapy after undergoing total pancreatectomy for a nonfunctional pancreatic neuroendocrine tumor (NET). The secretion of both endogenous insulin and pancreatic glucagon were completely depleted. Octreotide long acting repeatable (Oct-LAR) was administered for the treatment of liver metastasis of NET. Both the fasting and postprandial glucagon levels decreased immediately after the administration of Oct-LAR. In a continuous glucose monitoring analysis, episodes of nocturnal hypoglycemia was found to increase and an improvement of postprandial hyperglycemia was observed. This case suggests that octreotide may reduce the glucose level in both the fasting and postprandial states, in part by the suppression of extrapancreatic glucagon.

UR - http://www.scopus.com/inward/record.url?scp=85034262699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034262699&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.8963-17

DO - 10.2169/internalmedicine.8963-17

M3 - Article

C2 - 28943578

AN - SCOPUS:85034262699

VL - 56

SP - 3061

EP - 3066

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 22

ER -